Illumina (ILMN) Deep Dive: The Shovel Seller's Real Position in the AI Gold Rush

ProfitVision LAB｜AI BioTech Series｜April 2026

1. A Foundational Premise: Gene Sequencing Is the Bedrock of All AI Biotech

Before we discuss Illumina, we need to establish a conceptual framework — otherwise it's easy to underestimate its strategic position.

Every AI biotech revolution you've heard about — AI-designed drug molecules, machine learning that predicts protein structures, large language models analyzing genomic data, personalized cancer treatment — shares one common prerequisite: you must first have data. And the overwhelming majority of that data comes from a single source: gene sequencing.

Gene sequencing is the process of reading out an organism's DNA or RNA. Without sequencing, you have no genomic data; without genomic data, AI models have nothing to train on; without a trained model, so-called AI drug discovery is just an empty concept. The multimodal data Tempus AI prides itself on has genomic data as its most central layer — and a huge share of that data comes from Illumina's sequencers. The physical simulations Schrödinger uses to design drug molecules require understanding the three-dimensional structure of target proteins, and the underlying data for those structures likewise depends on sequencing technology.

This is Illumina's fundamental position: it isn't the protagonist of the AI biotech story, but it is the precondition for that story to happen at all. In the entire knowledge-production chain of the life sciences, Illumina's sequencers sit at the very top of the stream — everyone has to use them before they can do anything downstream.

And from that position, Illumina has done something that has made it nearly impossible to replace: over the past two decades, it has driven the cost of gene sequencing from an astronomical figure down to something almost negligible.

2. The Collapse in Sequencing Costs: One of the Most Astonishing Price Curves in the History of Technology

In 2001, the Human Genome Project completed the first full sequencing of a human genome, at a cost of about $2.7 billion and taking thirteen years. By 2007, the cost had fallen to tens of millions of dollars. By 2014, Illumina launched the HiSeq X Ten, announcing that whole-genome sequencing had dropped below $1,000. By 2023, the launch of the NovaSeq X pushed the cost down further to around $200.

This cost curve is not merely a technical achievement — it is the core of Illumina's business strategy. Every major compression in cost has opened a new application: $1,000 sequencing made personalized genetic testing for cancer treatment feasible; $200 sequencing made large-scale population genomics a routine operation; if cost continues falling toward $50, newborn whole-genome sequencing could become a standard medical procedure. Every order-of-magnitude drop in cost expands demand by an order of magnitude, and the consumables revenue generated by that demand flows back to Illumina.

3. The Essence of the Business Model: Razor and Blade — Except the Razor Isn't Cheap Either

Illumina's business model is often compared to "razor and blade" — sell a cheap razor (the sequencer), then make money on the blades (consumables). That comparison is broadly right but not quite precise, because Illumina's "razor" is itself not cheap: a NovaSeq X sells for around $1 million, and even a MiSeq costs over $100,000.

A more accurate description is: what Illumina really sells is admission into a closed ecosystem. Once you buy an Illumina sequencer, you enter Illumina's ecosystem — you must run Illumina's reagent kits to perform sequencing, because they are designed specifically for Illumina instruments and are not interchangeable with other brands' machines. Those reagent kits are the real cash cow: high gross margin, recurring consumption, and demand directly tied to the installed base of instruments.

The subtlety of this business model lies in its time dimension. A NovaSeq X has a design life of seven to ten years, and during that period the lab running the machine consumes a large volume of reagent kits, flow cells, and other consumables every year. In other words, every instrument sold today is a seven-to-ten-year forward order for consumables.

4. The Moat: Why an 80% Market Share Is Not a Coincidence but a Structure

Illumina holds more than 80% of the global short-read sequencing market. In any industry, that number would count as monopolistic — but in Illumina's case, this dominance doesn't come from anti-competitive behavior; it comes from a multi-layered structural moat.

The first layer of the moat is technological accumulation. Illumina's SBS (Sequencing by Synthesis) technology was built up over years of R&D and acquisitions, and involves thousands of patents. This is not a technology gap a competitor can close in a few years.

The second layer is standardization of data formats. The world's genomic databases, academic papers, and clinical standards are all built on Illumina's sequencing formats. All analysis software, workflows, and validation protocols are optimized for Illumina's output format. If a lab switches away from Illumina, it must revalidate its entire downstream analysis pipeline — that's not just a technical problem but a regulatory one, since many medical-use sequencing applications must run on a validated platform.

The third layer is a talent ecosystem. Most of the world's genomics-trained scientists learned on the Illumina platform. Illumina's interface, data formats, and analysis tools are the language they're fluent in. This talent-ecosystem effect means switching to another platform costs more than just new machines and reagents — it also means retraining people and losing productivity in the interim.

A question worth considering: Oxford Nanopore (long-read sequencing) and Pacific Biosciences (PacBio) are both challenging Illumina's position, and in specific applications (such as full-length transcriptomics and structural-variant analysis) they genuinely hold an advantage. But these technologies are "complementary" rather than "substitutive." The cost advantage and data quality of short-read sequencing keep it the preferred choice in mainstream applications like large-scale population genomics and cancer screening. Illumina doesn't need to win in every use case — it only needs to keep its dominant position in the largest market.

5. The GRAIL Episode: An Expensive Lesson, and the Aftershocks It Left Behind

To understand today's Illumina, you have to confront a costly mistake the company made in 2021: reacquiring GRAIL for $7.1 billion.

GRAIL is an early-cancer liquid-biopsy testing company that was originally spun out of Illumina. In 2021, Illumina attempted to bring it back in-house, arguing that GRAIL's multi-cancer early-detection technology (the Galleri blood test) required extensive Illumina sequencing, and that integrating the two would create synergies. That logic wasn't entirely wrong, but the execution contained a fatal error: Illumina closed the acquisition before it had been approved by regulators in the EU and the US.

The result was a prolonged regulatory war. The European Commission found the acquisition violated competition law and ordered Illumina to divest GRAIL; the US Federal Trade Commission also raised objections. Illumina finally completed the GRAIL divestiture in 2024, after an ordeal that consumed enormous management effort, legal costs, and billions of dollars in goodwill impairment.

The episode's impact on Illumina was multifaceted: financially, the related losses and charges severely weighed down its 2022–2024 reported results; on the management side, former CEO Francis deSouza stepped down under board pressure; strategically, the company had to refocus on its core business.

But the episode also had one positive consequence: it forced Illumina back to what it's genuinely good at — building sequencers and selling consumables. Since 2024, under new CEO Jacob Thaysen, Illumina has been refocusing: cutting costs, improving margins, accelerating NovaSeq X market penetration, and rebuilding customer relationships.

6. Illumina's AI Response Strategy: Ride the Wave, Lock In, or Counterattack?

This is one of the most central questions in this article, and also the most debated point in the market: is the AI era an opportunity or a threat for Illumina?

On the surface, AI looks like an unambiguous tailwind for Illumina: AI is driving demand for genomic data, more data demand means more sequencing volume, and more sequencing volume means more consumables revenue. That logic is correct but incomplete. Because AI also brings a potential threat: as AI compute capability improves, could it eventually become possible to "infer" or "synthesize" more genomic information from less physical sequencing data? If so, demand growth for physical sequencing might grow more slowly than expected.

Illumina's AI response strategy can be broken into three layers, each representing a different strategic logic:

7. Financial Snapshot: The GRAIL Aftershocks Are Fading, and Refocusing Is Paying Off

From 2022 to 2024, Illumina's financial statements were a disaster — not because the core business collapsed, but because GRAIL-related charges, impairments, and legal costs badly distorted the income statement. But strip out GRAIL's impact and look at the core sequencing business, and the picture is far clearer.

With the GRAIL divestiture completed in 2024, Illumina's balance sheet has begun to clear up. New CEO Jacob Thaysen launched a cost-cutting plan targeting a return to a Non-GAAP operating margin above 20% in 2025, with continued cash-flow improvement. NovaSeq X market penetration is still underway — as customers on older instrument models upgrade to the NovaSeq X, there can be a temporary short-term dip in consumables revenue (because the new model's reagent kits differ from the old one's), but over the long run this brings higher throughput and higher consumables revenue.

This "upgrade cycle" is the key dynamic Illumina investors need to track over the next 2 to 3 years: if NovaSeq X penetration keeps rising while AI-driven sequencing demand keeps growing, Illumina's consumables revenue has a real chance of returning to, and surpassing, its 2021 peak.

8. Risks: Not Absent, but Need to Separate Short Term from Long Term

9. Investment Strategy: Not a Growth Stock, Not a Decline Story Either — It's Compounding Through a Cycle

Illumina's current investment thesis is more complicated than Veeva's, but also more interesting than the market's perception. It is not a "sit back and collect income" stable asset — it carries scars left by GRAIL, near-term turbulence from the NovaSeq X upgrade cycle, and long-term threats from competing technologies. But nor is it a company with deteriorating fundamentals — its core market position remains solid, the AI trend is a tailwind, and the compounding of consumables revenue from the installed base is still running.

The most precise positioning is this: Illumina is a high-moat company recovering from the disruption of a specific event (GRAIL). If the recovery goes smoothly, it offers upside beyond the current valuation; if the recovery is slower than hoped, or competitive pressure proves stronger than expected, its moat is still deep enough to prevent a collapse in value.

10. Conclusion: The True Position of the Shovel Seller in the AI Gold Rush

Across this AI biotech series, we've seen four distinct investment theses: Tempus is a bet on whether the "data flywheel" can spin; Veeva is a bet on whether institutional switching costs can hold; Illumina is a bet on whether the act of sequencing itself can keep expanding; and the next installment, SDGR, is a bet on whether a drug that succeeds someday can pay royalties.

Of these four theses, Illumina has the second-highest degree of certainty after Veeva — but its certainty comes from a different source: not from a lock-in effect, but from the unavoidable nature of the market position it occupies. As long as the life sciences keep advancing, as long as AI biotech keeps needing data, as long as genomics keeps becoming a mainstream medical tool, sequencing has to happen — and Illumina remains the primary way sequencing happens.

This is not a story that gets your pulse racing. But in investing, the stories that get your pulse racing and the stories that make you money over the long run have never been the same crowd.

The single most important line in this whole series:
Tempus sells data, Veeva collects a toll, SDGR is a bet on the future.
Illumina does something more fundamental: it sells the capability that lets all of this happen.

However AI changes drug discovery, this capability won't disappear — it will only be needed more often.

This article is for research and educational purposes only and does not constitute investment advice. Data sources: Illumina Inc. annual reports, 10-K filings, earnings-call presentations (FY2021–FY2024), and the NIH genome sequencing cost database. Investing carries risk; please conduct your own due diligence.